Dr Catherine Booth
(Chief Executive Officer)
Cath co-founded Epistem in 2000 and led an MBO in 2018 in order to regain its independence from Genedrive plc. Cath has a BSc from Brunel University and a PhD from Cambridge University/The MRC Laboratory of Molecular Biology. After 10 years working in epithelial stem cell research in Professor Christopher Potten's lab at the Cancer Research UK Paterson Institute, Cath co-founded Epistem with Professor Potten. Since then she has managed the Epistem Services team, serving on the board of both the private company and plc (following its flotation on AIM in 2007).
(Chief Financial Officer)
James joined Epistem from his role as Finance Director for the Discovery division of Concept Life Sciences. James’ other previous roles were with the Ministry of Defence and then with a private equity-backed wholesaler. James has a BA from Durham University, an MBA from Bond University, Australia, and is a member of the Chartered Institute of Management Accountants.
Dr Ben Reed
Ben has over 20 years’ experience in the contract research services and diagnostics industry, much of which has been spent within protein detection and molecular biology products and services. Ben joined Epistem in 2009. He has previous commercial roles at Ciphergen, Oxford Biotherapeutics and PrimerDesign. Ben has a BSc from Monash University, Melbourne and a PhD from La Trobe University in Melbourne.
Julie is a founder member of Epistem, joining the company in 2000. After graduating with a BSc Julie worked as a Research Assistant with Cath Booth and Chris Potten at the Cancer Research UK Paterson Institute from 1995-2000. At Epistem she moved from Research Scientist/Study Manager to Operations in 2007 and became Operations Director following the MBO in 2018.
Dr Nick Ash
Nick has extensive experience at senior Board level in listed and private equity-backed companies in the life sciences sector. Prior to joining Epistem, Nick was CEO of Source BioScience plc for 12 years and spent 10 years with KPMG. Nick holds a BSc and a PhD in Biological Sciences from the University of Sheffield and is a Fellow of the Institute of Chartered Accountants in England and Wales.
Matthew is the Non-executive director of Epistem and works for Foresight Group. He has a background in investment and mergers and acquisitions. Matthew has a degree in Economics from the University of Sheffield and is a member of the Institute of Chartered Accountants in England and Wales.